3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2019
Price : $35 *
At a glance
- Drugs Eluxadoline (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allergan
- 26 Feb 2019 Planned End Date changed from 20 Jan 2019 to 7 Oct 2019.
- 26 Feb 2019 Planned primary completion date changed from 20 Jan 2019 to 30 Sep 2019.
- 26 Feb 2019 Status changed from recruiting to active, no longer recruiting.